Orion Oyj ORNBV.HE
Composite 71/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 36/100 — a moderate mark against it.
Growth ranks 86/100 — a strong point in its favour. Quality ranks 82/100 — a strong point in its favour. Balance-sheet strength ranks 82/100 — a strong point in its favour.
Valuation ranks 36/100 — a moderate mark against it.
What the company does Orion Oyj is a Nordic pharmaceutical group focused on human and veterinary drugs, APIs, and contract manufacturing. Its portfolio includes proprietary brands such as Nubeqa (prostate cancer), Entacapone (Parkinson’s), and the Easyhaler franchise for respiratory diseases, alongside contract-manufactured generics.
Key financials Orion posts exceptional profitability metrics: ROE 53.6%, ROA 26.3%, gross margin 65.9%, operating margin 33.8%, and net margin 28.5%. Revenue grew 25.2% and EPS 69.5%, supported by a strong balance sheet (debt/equity 0.10, current ratio 2.64).
Stock health Momentum is strong: 3m +23.04%, 6m +14.44%, 12m +19.60%, with RSI(14) at 72.90. SIDERAVIA ranks Orion 70.1/100 overall, citing excellent quality (83.5) and growth (85.2) but only middling valuation (34.1).
Price vs fair value The stock trades at a PREMIUM of 49.20% to our fair-value estimate of 41.82 and a PREMIUM of 6.99% to the average 12-month target of 76.50. - Forward P/E of 29.50 (vs trailing 19.32) signals rich near-term valuation. - EV/EBITDA at 15.03 and P/B at 8.83 remain elevated versus peers. - Momentum is stretched (RSI 72.90) despite strong fundamentals.
Looking forward Analysts expect continued growth, but current multiples embed high expectations. Execution on pipeline and margin stability will determine whether the premium is sustainable.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.